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Hydration for CI-AKI Prevention
“Salus Per Aquam” (Health Through Water)*Antonio L. Bartorelli, MD,a,b Giancarlo Marenzi, MDaC ontrast-induced acute kidney injury (CI-AKI)is one of the leading causes of hospital-acquired acute renal insufﬁciency, occurring
in approximately 12% of patients undergoing percuta-
neous coronary intervention (PCI). This complication
is associated with strikingly higher in-hospital and
long-term morbidity and mortality, persistent loss of
kidney function, and risk of progression to end-
stage renal disease. Pre-existing chronic kidney dis-
ease (CKD), advanced age, diabetes, and urgent and
emergency PCI increase the risk of CI-AKI up to 30%
as compared with a 2% rate in the general population.
Because CI-AKI is predictable in most cases, preven-
tive strategies are the only effective therapeutic
approach. Accordingly, several studies have been
focusing on prevention, most often with pharmaco-
logical agents. However, none of the tested drugs
showed irrefutable positive effects, particularly in pa-
tients with severe CKD. Exceptions to rather disap-
pointing results are limiting contrast dosages and
adequate intravenous pre-procedural hydration. The
beneﬁcial effects of isotonic saline infusion have
been demonstrated in low-risk patients with normal
renal function, but they were not substantiated
beyond question in those with CKD. Current guide-
lines recommend isotonic saline at an infusion rate
of 1.0 ml/kg/h or less (0.5 ml/kg/h) in the case of left
ventricular ejection fraction (LVEF) <35% or New
York Heart Association functional class >2 (1).*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
From the aCentro Cardiologico Monzino, Istituto di Ricerca e Cura a
Carattere Scientiﬁco, Milan, Italy; and the bDepartment of Biomedical and
Clinical Sciences “Luigi Sacco”, University of Milan, Milan, Italy. Both
authors have reported that they have no relationships relevant to the
contents of this paper to disclose.However, the recommended hydration rate repre-
sents a “safe” regimen conceived to avoid ﬂuid over-
load and pulmonary edema, rather than to achieve a
“true” hydration. Thus, despite general agreement
on its beneﬁt, most patients do not receive sufﬁcient
hydration before contrast exposure. In particular,
patients at high risk due to severe LVEF depression
and/or advanced CKD, who may beneﬁt most from a
vigorous hydration, receive less ﬂuid volume than
those without cardiac and renal dysfunction. Indeed,
heavy systemic hydration in these patients is poorly
tolerated and potentially harmful. Interestingly,
whereas hydration remains the cornerstone for CI-
AKI prevention, a randomized controlled trial
comparing a strategy of volume expansion to no vol-
ume expansion has not been performed to date.
Another still controversial issue is the association
of hydration with diuretics. Current guidelines
recommend discontinuing diuretic agents, despite
their potential renal protective effects. Indeed, furo-
semide inhibits sodium-potassium-chloride cotrans-
port in the thick ascending limb of the Henle loop.
This nephron segment is at the greatest risk of
ischemic injury due to high metabolic demand and
low oxygen delivery. Notwithstanding the postulated
beneﬁts (reduction of renal oxygen consumption and
increased urine ﬂow leading to contrast dilution and
reduced direct toxicity on renal tubules), clinical
studies demonstrated that furosemide is associated
with increased CI-AKI incidence, likely due to intra-
vascular volume depletion.
Interestingly, the PRINCE (Prevention of Radio-
contrast Induced Nephropathy Clinical Evaluation)
study showed that forced diuresis, achieved with a
single diuretic dose in combination with intravenous
ﬂuid replacement matched to urine output, provided
a modest protective effect against CI-AKI (2).
This study demonstrated an inverse correlation
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365between urine ﬂow rate and creatinine increase after
contrast exposure, with a signiﬁcantly lower risk of
CI-AKI and dialysis when patients achieved a mean
urine ﬂow rate >150 ml/h. These results support the
concept that high urine output is required to protect
the kidney. On this premise, a strategy able to main-
tain the positive effects of furosemide-induced high-
volume diuresis and, at the same time, to preserve
intravascular volume (euvolemia) through simulta-
neous matched hydration should prevent CI-AKI in
high-risk patients.
The RenalGuard system (RenalGuard Solutions,
Milford, Massachusetts) has been developed in order
to achieve real-time, automated ﬂuid matching by
continuously measuring urine output—accelerated
by a bolus of intravenous furosemide—and replacing
it with an exactly matched amount of infused
ﬂuid volume. The system comprises a urinary
collection bag connected to a Foley catheter and hung
on a digital scale that drives a high-volume ﬂuid
pump. Any amount of urine entering the collection
bag results in an equal volume of saline infused
intravenously back to the patient. The infusion rate is
adjusted milliliter for milliliter and second by second
in response to changes in urine output, thus pre-
venting net ﬂuid loss and ﬂuid overload. By admin-
istering a small bolus (250 ml) of ﬂuid initially and
stimulating diuresis with furosemide (0.25 to 0.5 mg/
kg), urine output increases to >300 ml/min in about
60 min, and this rate is maintained during the inter-
ventional procedure and for the following 4 h.SEE PAGE 355The results of the study published in this issue of
JACC: Cardiovascular Interventions (3) represent an
important piece of evidence by which to guide the
contemporary management of patients who are at
high risk of CI-AKI and undergo contrast-enhanced
procedures. Of note, this is the ﬁrst systematic re-
view and meta-analysis of the published randomized
trials that assessed the effect of the RenalGuard
system in patients undergoing coronary procedures
(diagnostic and interventional) and transcatheter
aortic valve replacement (TAVR). Undoubtedly, the
meta-analysis was well conducted using the
PRISMA guidelines. Four randomized trials, including
698 patients, were selected following the PICOS
criteria. The RenalGuard therapy was associated with
a signiﬁcant reduction of CI-AKI (7.76% vs. 21.43%;
p < 0.00001), a lower need for renal replacement
therapy (0.58% vs. 3.45%; p ¼ 0.02), and a nonsig-
niﬁcant lower rate of mortality, post-procedural acute
coronary syndrome, stroke, and acute pulmonary
edema. Of note, most of the patients treated with theRenalGuard reached high urine output despite
severely depressed kidney function without clinically
signiﬁcant changes in electrolyte balance and hemo-
dynamic or systemic adverse reactions. Although well
standardized and codiﬁed with the assistance of a
dedicated software, this meta-analysis may have
the common limitations of several previous meta-
analyses. Namely, it was on the basis of the overall
study populations and not on patient-level data.
Another limitation is the fact that the analyzed
studies were not powered to detect differences in
clinical outcome, they did not provide data on the
cost–beneﬁt ratio, and long-term (1-year) impact of
the RenalGuard therapy was reported by 1 trial only
(4). Nevertheless, the considerable magnitude of the
between-group differences in CI-AKI incidence and
the uniform positive results among all trials suggest
that it is quite unlikely that this is a faulty meta-
analysis with a signiﬁcantly incorrect assessment of
the RenalGuard treatment effect.
A pivotal trial (Evaluation of RenalGuard System to
Reduce the Incidence of Contrast Induced Nephropa-
thy in At-Risk Patients [CIN-RG]; NCT01456013)
involving up to 20 U.S. sites is in progress. The trial is
comparing RenalGuard plus N-acetylcysteine versus
saline (3 ml/kg bolus, 1.5 ml/kg during and 4 h after
angiography) plus N-acetylcysteine. The trial, whose
results are awaited with interest, has already ran-
domized 236 of 430 planned patients who are at high
risk of CI-AKI (estimated glomerular ﬁltration rate
[eGFR] 15 to 45 ml/min or 46 to 60 ml/min in case of 2
additional risk factors) and scheduled to receive$75ml
of contrast. The primary efﬁcacy endpoint is CI-AKI
occurrence, whereas secondary endpoints include
90-day mortality, myocardial infarction, stroke, heart
failure, and dialysis. Another randomized, sham-
controlled trial (REDUCE-AKI [The Effect of the
Forced Diuresis With Matched Hydration in Reducing
Acute Kidney Injury During TAVI]; NCT01866800) is
currently conducted in Israel to examine the effect
of RenalGuard for CIN-AKI prevention in patients
undergoing TAVR (5). Patients are randomized in a 1:1
fashion to the RenalGuard system (active group)
versus nonmatched saline infusion (sham-controlled
group). Moreover, in a recent investigator-driven,
single-center, retrospective analysis of prospectively
collected data, the RenalGuard therapy resulted in
lower CI-AKI incidence and, unexpectedly, in signiﬁ-
cant eGFR improvement in high-risk patients under-
going coronary angiography, PCI, or TAVR (6). This
may suggest that, besides the supposed beneﬁcial
effects of the RenalGuard (faster transit through the
tubules, decreased luminal concentration, and
reduction in sludging and precipitation of the
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366contrast), other mechanisms may play a role and
should be further investigated. In this regard, some
insights can be inferred from the data of the MYTHOS
(Induced Diuresis With Matched Hydration Compared
to Standard Hydration for Contrast Induced Ne-
phropathy Prevention) trial (7). This trial indicates
that RenalGuard-treated patients achieve a signiﬁ-
cantly higher volume of renal-targeted hydration
(4,000 ml vs. 1,750 ml) in a much shorter time (6 h vs.
24 h) than those treated with standard systemic hy-
dration, markedly amplifying the kidney protective
effects of hydration.
In conclusion, despite the limitations that are
common to all meta-analyses and the smallnumber of trials published, the authors must be
complimented for this important study. The results
of their meta-analysis, along with those of other
multicenter randomized trials that are needed to
corroborate the present ﬁndings, suggest that
furosemide-induced high-volume diuresis and
maintenance of euvolemia through matched ﬂuid
replacement (RenalGuard therapy) might become a
standard of care strategy for the prevention of
CI-AKI in high-risk patients.
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